Drugs / TC011
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07473167 | Aug 2023 → Feb 2028 expected | follicular lymphoma, high grade B-cell lymphoma, large B-cell lymphoma, primary mediastinal large B-cell lymphoma | TICAROS Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07360288 | Mar 2026 → May 2028 expected | follicular lymphoma | TICAROS Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TC011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07473167 ↗ |
| Modality | Cell therapy | “Anti-CD19 Chimeric Antigen Receptor T cell” NCT07473167 ↗ |
| Route | Intravenous | “a single intravenous infusion of TC011” NCT07360288 ↗ |
| Target | CD19 | “CD19 Targeted CAR-T” NCT07473167 ↗ |